Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of AZD5718 formulations in healthy volunteers
NCT04734275Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atuliflapon in chronic kidney disease (CKD) (3 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from zero to infinity, Area under the plasma concentration-time curve from zero to the last quantifiable concentration and 2 more. Started Feb 2021; status: completed.
02
Drugs
atuliflapon
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04734275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04734275.